Journal
IMMUNOTHERAPY
Volume 13, Issue 17, Pages 1427-1438Publisher
FUTURE MEDICINE LTD
DOI: 10.2217/imt-2021-0241
Keywords
immunogenic cell death; IRDye700DX; near infrared photoimmunotherapy; photo-based medicine; targeted cancer immunotherapy
Categories
Ask authors/readers for more resources
NIR-PIT is a highly specific cancer treatment that leads to rapid immunogenic cell death. Despite being effective and innovative, challenges such as limited light penetration, target selection, concerns about tumor lysis syndrome, and drug costs exist. However, it has been approved in Japan, allowing for exploration on how to overcome these challenges and maximize benefits.
Near infrared photoimmunotherapy (NIR-PIT) is a molecularly targeted treatment for cancers achieved by injecting a conjugate of IRDye700DX(R) (IR700), a water-soluble silicon phthalocyanine derivative in the near infrared, and a monoclonal antibody that targets cancer cell antigens. NIR-PIT is a highly specific treatment with few side effects that results in rapid immunogenic cell death. Despite it being a very effective and innovative therapy, there are a few challenges preventing full implementation in clinical practice. These include the limits of near infrared light penetration, selection of targets, concerns about tumor lysis syndrome and drug costs. However, NIR-PIT has been approved by the regulatory authorities in Japan, allowing for exploration of how to mitigate challenges while maximizing the benefits of this treatment modality.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available